<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        321-334-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        INCRESYNC 25/45 mg Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ALOGLIPTIN,PIOGLITAZONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25,45
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        175.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="TAKEDA PHARMACEUTICAL COMPANY LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            TAKEDA PHARMACEUTICAL COMPANY LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BD09 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Incresync contains two different medicines called alogliptin and pioglitazone in one tablet:</p><ul><li>&nbsp;Alogliptin belongs to a group of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors). Alogliptin works to increase the levels of insulin in the body after a meal and decrease the amount of sugar in the body.</li><li>&nbsp; Pioglitazone belongs to a group of medicines called thiazolidinediones. It helps your body make better use of the insulin it produces.</li></ul><p>Both of these groups of medicines are &ldquo;oral anti- diabetics&rdquo;.</p><p><strong>What Incresync is used for</strong></p><p>Incresync is used to lower blood sugar levels in adults with type 2 diabetes. Type 2 diabetes is also called non- insulin-dependent diabetes mellitus or NIDDM.</p><p>Incresync is taken when your blood sugar cannot be adequately controlled by diet, exercise and other oral anti-diabetic medicines such as pioglitazone; or pioglitazone and metformin taken together. Your doctor will check whether Incresync is working 3 to 6 months after you start taking it.</p><p>If you are already taking both alogliptin and pioglitazone as single tablets, Incresync can replace them in one tablet.</p><p>It is important that you continue to follow the advice on diet and exercise that your nurse or doctor has given you.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Incresync </strong></p><ul><li>&nbsp; &nbsp;If you are allergic to alogliptin, pioglitazone or any of the other ingredients of this medicine (listed in section 6).</li><li>&nbsp;If you have had a serious allergic reaction to any other similar medicines that you take to control your blood sugar. Symptoms of a serious allergic reaction may include; rash, raised red patches on your skin (hives), swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing. Additional symptoms may include general itching and feeling of heat especially affecting the scalp, mouth, throat, palms of hands and soles of feet (Stevens-Johnson syndrome).</li><li>&nbsp; &nbsp;If you have heart failure or have had heart failure in the past.</li><li>&nbsp; &nbsp;If you have liver disease.</li><li>&nbsp; &nbsp;If you have diabetic ketoacidosis (a serious complication of poorly controlled diabetes).</li></ul><p>Symptoms include excessive thirst, frequent urination, loss of appetite, nausea or vomiting and rapid weight loss.</p><ul><li>&nbsp; &nbsp;If you have or have ever had bladder cancer.</li><li>&nbsp; &nbsp;If you have blood in your urine that your doctor has not checked. Do not take Incresync and get your doctor to check your urine as soon as possible.</li></ul><p><strong>Warnings and Precautions </strong></p><p>Talk to your doctor or pharmacist before taking Incresync:</p><ul><li>&nbsp; If you have type 1 diabetes (your body does not produce insulin).</li><li>&nbsp; If you are taking an anti-diabetic medicine known as sulphonylurea (e.g. glipizide, tolbutamide, glibenclamide) or insulin.</li><li>&nbsp; If you suffer from heart disease or fluid retention. If you take anti-inflammatory medicines which can also cause fluid retention and swelling, you must also tell your doctor.</li><li>&nbsp; If you are elderly and are taking insulin, because you may have an increased risk of heart problems.</li><li>&nbsp; &nbsp;If you have a problem with your liver or kidneys. Before you start taking this medicine you will have a blood sample taken to check your liver and kidney function. This check may be repeated at intervals. In case of kidney disease, your doctor may reduce the dose of Incresync.</li><li>&nbsp; If you have a special type of diabetic eye disease called macular oedema (swelling of the back of the eye).</li><li>&nbsp; If you have cysts on your ovaries (polycystic ovarian syndrome). There may be an increased possibility of becoming pregnant because you may ovulate again when you take Incresync. If this applies to you, use appropriate contraception to avoid the possibility of an unplanned pregnancy.</li><li>&nbsp; &nbsp;If you have or have had a disease of the pancreas.</li></ul><p>Slight changes in cell counts may show up in blood tests. Your doctor may discuss the results with you.</p><p>A higher number of bone fractures was seen in patients, particularly women taking pioglitazone. Your doctor will take this into account when treating your diabetes.</p><p><strong>Children and adolescents</strong></p><p>Incresync is not recommended for children and adolescents under 18 years due to the lack of data in these patients.</p><p><strong>&nbsp;Other medicines and Incresync</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>In particular tell your doctor or pharmacist if you are taking any of the following:</p><ul><li>&nbsp; &nbsp; Gemfibrozil (used to lower cholesterol)</li><li>&nbsp; &nbsp; Rifampicin (used to treat tuberculosis and other infections)</li></ul><p>Your blood sugar will be checked and your dose of Incresync may need to be changed.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>There is no experience of using Incresync in pregnant women or during breast-feeding. Incresync should not be used during pregnancy or breast-feeding.</p><p><strong>Driving and using machines </strong></p><p>You may experience visual disturbances while taking this medicine. If this happens, do not drive or use any tools or machines. Taking Incresync in combination with other anti-diabetic medicines can cause low blood sugar levels (hypoglycaemia), which may affect your ability to drive and use machines.</p><p><strong>Incresync contains lactose monohydrate</strong></p><p>Incresync contains lactose monohydrate.</p><p>Each 25 mg/45 mg film-coated tablet contains 110.43 mg lactose monohydrate.</p><p>If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking Incresync.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Your doctor will tell you how much Incresync you need to take and if you need to change the amount of other medicines you take.</p><p>The maximum recommended daily dose is 25 mg alogliptin and 45 mg pioglitazone.</p><p>Incresync should be taken once daily. Swallow your tablet(s) whole with water. You can take this medicine with or without food.</p><p>If you have kidney problems your doctor may prescribe you a reduced dose.</p><p>If you are following a diabetic diet, you should continue with this while you are taking Incresync.</p><p>Your weight should be checked at regular intervals; if your weight increases, tell your doctor.</p><p><strong>If you take more Incresync </strong><strong>than you should</strong></p><p>If you take more tablets than you should, or if someone else or a child takes your medicine, contact or go to your nearest emergency centre straight away. Take this leaflet or some tablets with you so that your doctor knows exactly what you have taken.</p><p><strong>&nbsp;If you forget to take Incresync</strong></p><p>If you forget to take a dose, take it as soon as you remember it. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Incresync</strong></p><p>Do not stop taking Incresync without consulting your doctor first. Your blood sugar levels may increase when you stop taking Incresync.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>STOP taking Incresync and contact a doctor immediately if you notice any of the following serious side effects:</p><p><strong>Common</strong> (may affect up to 1 in 10 people):</p><ul><li>Sudden and severe bone pain or immobility (particularly in women).</li></ul><p><strong>Uncommon</strong> (may affect up to 1 in 100 people):</p><ul><li>Symptoms of bladder cancer including blood in your urine, pain when urinating or a sudden need to urinate.</li></ul><p><strong>Not known</strong> (frequency cannot be estimated from the available data):</p><ul><li>An allergic reaction. The symptoms may include: a rash, hives, swallowing or breathing problems, swelling of your lips, face, throat or tongue and feeling faint.</li><li>A severe allergic reaction: skin lesions or spots on your skin that can progress to a sore surrounded by pale or red rings, blistering and/or peeling of the skin possibly with symptoms such as itching, fever, overall ill feeling, achy joints, vision problems, burning, painful or itchy eyes and mouth sores (Stevens-Johnson syndrome and Erythema multiforme).</li><li>Severe and persistent pain in the abdomen (stomach area) which might reach through to your back, as well as nausea and vomiting, as it could be a sign of an inflamed pancreas (pancreatitis).</li></ul><p>You should also discuss with your doctor if you experience the following side effects:</p><p><strong>Common:</strong></p><ul><li>Symptoms of low blood sugar (hypoglycaemia) may occur when Incresync is taken in combination with insulin or sulphonylureas (e.g. glipizide, tolbutamide, glibenclamide). Symptoms may include: trembling, sweating, anxiety, blurred vision, tingling lips, paleness, mood change or feeling confused. Your blood sugar could fall below the normal level, but can be increased again by taking sugar. It is recommended that you carry some sugar lumps, sweets, biscuits or sugary fruit juice.</li><li>Cold or flu-like symptoms such as sore throat, stuffy or blocked nose</li><li>Inflammation of the sinuses (sinusitis)</li><li>Itchy skin</li><li>Headache</li><li>Stomach ache</li><li>Diarrhoea</li><li>Indigestion, heartburn</li><li>Feeling sick</li><li>Muscle pain</li><li>Feeling numb in any part of your body</li><li>Blurred or distorted vision</li><li>Weight gain</li><li>Swollen or puffy hands or feet</li><li>Rash</li></ul><p><strong>Uncommon:</strong></p><ul><li>Difficulty sleeping</li></ul><p><strong>Not known:</strong></p><ul><li>Visual disturbances (caused by a condition called macular oedema).</li><li>Liver problems such as nausea or vomiting, stomach pain, unusual or unexplained tiredness, loss of appetite, dark urine or yellowing of your skin or the whites of your eyes.</li></ul><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are alogliptin benzoate and pioglitazone hydrochloride.</p><p>Each Incresync 25 mg/45 mg Film-coated Tablet contains 34 mg alogliptin benzoate equivalent to 25 mg alogliptin and 49.59 mg pioglitazone hydrochloride equivalent to 45 mg pioglitazone.</p><p>The other ingredients are: <em>Tablet core:</em> Mannitol, microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, magnesium stearate and lactose monohydrate. <em>Film-coating:</em> Hypromellose, polyethylene glycol, titanium dioxide, talc and ferric oxide red. <em>Printing ink:</em> Gray F1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Incresync 25 mg/45 mg Film-coated Tablets are red round biconvex film-coated tablets, with both “A/P” and “25/45” printed on one side in aluminum blisters.
Pack size: 28 Film-coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 4980170&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br />Fax: + (966-11) 4980187<br />e-mail: <u>medical@jpi.com.sa</u></p><p><strong>Manufacturer</strong></p><p>Takeda Pharmaceutical Company Limited</p><p>17-85, Jusohonmachi, 2-chome</p><p>Osaka 532-8686, Japan</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 10/2018; version number vSA1.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي انكرسينك على دوائين مختلفين في قرص واحد وهما الألوغليبتين&nbsp;والبيوغليتازون:</p><ul dir="rtl"><li>ينتمي الألوغليبتين إلى مجموعة الأدوية التي تدعى مثبطات ثنائي ببتيديل ببتيداز-4. يعمل الألوغليبتين على زيادة مستويات الأنسولين في الجسم بعد تناول الوجبة الغذائية ويعمل على تقليل كمية السكر في الجسم.</li><li>ينتمي البيوغليتازون إلى مجموعة الأدوية التي تدعى بالثيازوليدينديون. تساعد جسمك على الاستفادة بشكل أفضل من الأنسولين الذي يتم إنتاجه.</li></ul><p dir="RTL">كلتا المجموعتين من الأدوية هي &quot;خافضات السكر التي تعطى عن طريق الفم&quot;.</p><p dir="RTL"><strong>ما هي دواعي استخدام </strong><strong>انكرسينك</strong></p><p dir="RTL">يستخدم انكرسينك لخفض مستويات السكر في الدم لدى البالغين المصابين بداء السكري من النوع الثاني. يسمى مرض السكري من النوع الثاني أيضاً بمرض السكري غير المعتمد على الأنسولين.</p><p dir="RTL">يتم تناول انكرسينك عندما لا يتم التحكم بشكل كافٍ في نسبة السكر في الدم عن طريق النظام الغذائي، التمارين الرياضية وعن طريق الأدوية الأخرى لخفض السكري مثل البيوغليتازون؛ أو عند تناول البيوغليتازون&nbsp;&nbsp;والميتفورمين معاً. سيتحقق طبيبك مما إذا كان انكرسينك يعمل من 3 إلى 6 أشهر بعد البدء بتناوله.</p><p dir="RTL">إذا كنت تتناول بالفعل كلاً من الالوغليبتين&nbsp;والبيوغليتازون&nbsp;كأقراص منفردة، فيمكن استبدالهما بقرص واحد من انكرسينك.</p><p dir="RTL">من المهم أن تستمر في متابعة النصائح المتعلقة بالنظام الغذائي والتمارين الرياضية التي قدمها لك ممرضك أو طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم </strong><strong>انكرسينك</strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية تجاه الألوغليبتين، البيوغليتازون أو أي من المكونات الأخرى في هذا الدواء (المذكورة في القسم 6).</li><li>إذا سبق وحدث لديك رد فعل تحسسي خطير لأي أدوية أخرى مشابهة والتي تتناولها للسيطرة على مستوى السكر في دمك. تتضمن أعراض رد الفعل التحسسي الخطير؛ طفح جلدي، بقع بارزة لونها أحمر على جلدك (شرى)، تورم في الوجه، الشفتين، اللسان والحلق والذي قد يؤدي إلى صعوبة في التنفس أوا لبلع. قد تتضمن الأعراض الإضافية حكة عامة وشعور بالحرارة خاصة في فروة الرأس، الفم، الحلق، راحة اليدين وأخمص القدمين (متلازمة ستيفنز جونسون).</li><li>إذا كنت تعاني من قصور القلب أو سبق وعانيت من قصور القلب في الماضي.</li><li>إذا كنت تعاني من مرض في الكبد.</li><li>إذا كنت تعاني من حُماض كيتوني سكري (من المضاعفات الخطيرة الناتجة عن مرض السكري غير المسيطر عليه بشكل جيد).</li></ul><p dir="RTL">تتضمن الأعراض العطش الشديد، التبول المتكرر، فقدان الشهية، غثيان أو قيء وفقدان سريع في الوزن.</p><ul dir="rtl"><li>&nbsp;إذا كنت تعاني أو عانيت مسبقاً من سرطان في المثانة.</li><li>&nbsp;إذا كان لديك دم في البول لم يفحصه طبيبك. لا تتناول انكرسينك واذهب لطبيبك لفحص البول في أقرب وقت ممكن.</li></ul><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل تناول انكرسينك:</p><ul dir="rtl"><li>إذا كنت تعاني من مرض السكري النوع الأول (عندما لا يملك جسمك القدرة على تصنيع الأنسولين).</li><li>إذا كنت تتناول أدوية خافضة للسكر والتي تعرف بالسلفونيليوريا (مثل غليبيزيد، تولبوتاميد، غليبانكلاميد) أو الأنسولين.</li><li>إذا كنت تعاني من مرض في القلب أو احتباس السوائل. إذا كنت تتناول الأدوية المضادة للالتهابات والتي يمكن أيضاً أن تسبب احتباس السوائل والتورم، فيجب عليك أيضاً إخبار الطبيب بذلك.</li><li>&nbsp;إذا كنت من كبار السن وتأخذ الأنسولين، فقد يزيد خطر إصابتك بمشاكل في القلب.</li><li>إذا كنت تعاني من مشكلة في الكبد أو الكليتين. قبل البدء بتناول هذا الدواء، سيتم سحب عينة دم منك لفحص وظائف الكبد والكلى لديك. قد يتكرر هذا الفحص على فترات. في حال الإصابة بمرض في الكلى، قد يقوم طبيبك بتقليل جرعة انكرسينك.</li><li>إذا كنت تعاني من نوع خاص من اعتلال الشبكية السكري يسمى الوذمة البقعية (تورم الجزء الخلفي من العين).</li><li>إذا كنت تعانين من أكياس على المبايض (متلازمة تكيس المبايض). قد تزيد احتمالات حدوث حمل حيث قد تحدث الإباضة من جديد عندما تتناولين انكرسينك. إذا كان هذا ينطبق عليك، فاستخدمي وسائل منع الحمل المناسبة لتجنب احتمال حدوث حمل غير مخطط له.</li><li>إذا كنت تعاني أو عانيت مسبقاً من مرض في البنكرياس.</li></ul><p dir="RTL">قد تظهر تغيرات طفيفة في عدد الخلايا في فحوصات الدم. قد يناقش طبيبك النتائج معك.</p><p dir="RTL">لوحظ حدوث عدد أكبر من كسور العظام في المرضى الذين يأخذون بيوغليتازون، وخاصةً النساء منهم. سيضع طبيبك ذلك في عين الاعتبار عند علاج مرض السكري لديك.</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">لا يوصى بإعطاء انكرسينك للأطفال والمراهقين دون سن 18 عاماً بسبب نقص البيانات في هؤلاء المرضى.</p><p dir="RTL"><strong>الأدوية الأخرى و</strong><strong>انكرسينك</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً، أو قد تتناول أية أدوية أخرى.</p><p dir="RTL">أخبر طبيبك أو الصيدلي بشكل خاص إذا كنت تتناول أيّاً مما يلي:</p><ul dir="rtl"><li>جامفيبروزيل (يستخدم لخفض الكوليسترول)</li><li>ريفامبيسين (يستخدم لعلاج السل وأنواع أخرى من العدوى)</li></ul><p dir="RTL">سيتم فحص السكر في الدم لديك وقد تحتاج إلى تغيير جرعة انكرسينك.</p><p dir="RTL"><strong>الحمل والرضاعة</strong><strong> </strong></p><p dir="RTL">يرجى استشارة طبيبك أو الصيدلي للحصول على النصيحة قبل تناول هذا الدواء إذا كنت حاملاً أو تقومين بالرضاعة الطبيعية، تعتقدين بأنك قد تكونين حاملاً أو تخططين لإنجاب طفل.</p><p dir="RTL">لا تتوفر الخبرة في استخدام انكرسينك لدى النساء الحوامل أو خلال الرضاعة الطبيعية. لا يجب استخدام انكرسينك خلال الحمل أو الرضاعة الطبيعية.</p><p dir="RTL"><strong>تأثير </strong><strong>انكرسينك</strong><strong> </strong><strong>على القيادة واستخدام الآلات</strong></p><p dir="RTL">قد تواجه اضطرابات بصرية أثناء تناول هذا الدواء. إذا حدث ذلك، لا تقم بالقيادة أو استخدام أي أدوات أو آلات. تناول<strong> </strong>انكرسينك<strong> </strong>بالتزامن مع أدوية أخرى خافضة للسكر قد يؤدي إلى انخفاض مستويات السكر في الدم (نقص سكر الدم)، والتي قد تؤثر على قدرتك على القيادة واستخدام الآلات.</p><p dir="RTL"><strong>يحتوي </strong><strong>انكرسينك</strong><strong> </strong><strong>على لاكتوز أحادي الماء</strong></p><p dir="RTL">يحتوي انكرسينك على لاكتوز أحادي الماء.</p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة من 25 ملغم/45 ملغم على 110.43 ملغم لاكتوز أحادي الماء.</p><p dir="RTL">إذا أخبرك طبيبك بأن لديك حساسية تجاه بعض السكريات، اتصل بطبيبك قبل تناول انكرسينك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائماً بتناول هذا الدواء تماماً كما أخبرك طبيبك أو الصيدلي. تحقق مع طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL">سيخبرك طبيبك مقدار انكرسينك الذي تحتاج أن تتناوله وإذا كنت بحاجة إلى تغيير مقدار الأدوية الأخرى التي تتناولها.</p><p dir="RTL">الجرعة اليومية القصوى الموصى بها هي 25 ملغم الوغليبتين&nbsp;و45 ملغم بيوغليتازون.</p><p dir="RTL">يجب تناول انكرسينك مرة يومياً. قم ببلع الأقراص بالكامل مع الماء. بإمكانك تناول هذا الدواء مع الطعام أو بدونه.</p><p dir="RTL">إذا كنت تعاني من مشاكل في الكلى، فقد يصف لك طبيبك جرعة منخفضة.</p><p dir="RTL">إذا كنت تتبع نظاماً غذائياً لمرضى السكري، فيجب عليك متابعة ذلك أثناء تناولك لانكرسينك.</p><p dir="RTL">يجب فحص وزنك على فترات منتظمة؛ أخبر طبيبك في حال زاد وزنك.</p><p dir="RTL"><strong>إذا تناولت جرعة زائدة من </strong><strong>انكرسينك</strong></p><p dir="RTL">إذا تناولت أكثر مما يلزم من الأقراص، أو إذا تناول شخص آخر أو طفل&nbsp; دواؤك، اتصل أو اذهب إلى أقرب مركز طوارىء على الفور. قم بأخذ هذه النشرة أو بعض من الأقراص معك ليتمكن طبيبك من معرفة ما قمت بتناوله<strong> </strong>بالضبط.</p><p dir="RTL"><strong>إذا نسيت تناول </strong><strong>انكرسينك</strong></p><p dir="RTL">إذا نسيت تناول جرعة، قم بتناولها فور تذكرها. لا تقم بتناول جرعة مضاعفة للتعويض عن الجرعة المنسية.</p><p dir="RTL"><strong>إذا توقفت عن تناول </strong><strong>انكرسينك</strong></p><p dir="RTL">لا تتوقف عن تناول انكرسينك دون استشارة طبيبك أولاً. قد ترتفع مستويات السكر في دمك إذا توقفت عن تناول انكرسينك.</p><p dir="RTL">إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء، يرجى استشارة الطبيب أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL">توقف عن تناول انكرسينك واتصل بالطبيب على الفور إذا لاحظت أيّاً من الآثار الجانبية الخطيرة التالية:</p><p dir="RTL"><strong>شائعة </strong>(قد تؤثر على أكثر من شخص من 10 أشخاص):</p><ul><li>ألم مفاجئ وحاد في العظام أو عدم القدرة على الحركة (خاصة عند النساء).</li></ul><p dir="RTL"><strong>غير شائعة</strong> (قد تؤثر على أكثر من شخص من 100 شخص):</p><ul><li>أعراض سرطان المثانة وتشمل دم في البول، ألم عند التبول أو الحاجة إلى التبول فجأة.</li></ul><p dir="RTL"><strong>غير معروفة</strong> (لا يمكن تقدير تكرارها من البيانات المتاحة):</p><ul dir="rtl"><li>تفاعل تحسسي. قد تتضمن الأعراض: طفح جلدي، شرى، مشاكل في التنفس أو البلع، تورم في الشفتين، الوجه، الحلق أو اللسان والشعور بالإغماء.</li><li>تفاعل تحسسي شديد: آفات جلدية أو بقع على جلدك والتي قد تتطور إلى قرحة تحيطها حلقات باهتة أو حمراء اللون، تنفط و/أو تقشر الجلد مع احتمالية وجود أعراض مثل الحكة، الحمى، الشعور بالمرض بشكل عام، ألم في المفاصل، مشاكل في البصر، الشعور بحرقة، ألم أو حكة في العينين وتقرحات في الفم (متلازمة ستيفنز جونسون وحُمامى عديدة الأشكال). &nbsp;</li><li>ألم شديد ومستمر في البطن (منطقة المعدة) والذي قد يصل إلى الظهر، وكذلك الغثيان والقيء والذي قد يكون علامة على التهاب البنكرياس.</li></ul><p dir="RTL">كما يجب عليك أن تتناقش مع طبيبك إذا عانيت من أي من الأعراض الجانبية التالية:</p><p dir="RTL"><strong>شائعة:</strong></p><ul dir="rtl"><li>قد تحدث أعراض انخفاض مستوى السكر في الدم (نقص سكر الدم) عندما يتم تناول انكرسينك بالتزامن مع الأنسولين أو أدوية السلفونيليوريا (مثل غليبيزيد، تولبوتاميد، غليبانكلاميد).</li></ul><p dir="RTL"><em>تتضمن الأعراض:</em><em> </em>الإرتعاش، التعرق، القلق، عدم وضوح في الرؤية، نخز الشفتين، شحوب، تقلب المزاج أو الشعور بالارتباك. قد يهبط لديك مستوى السكر دون المستوى الطبيعي، لكن يمكن رفعه مرة أخرى بتناول السكر. يوصى بأن تبقي معك مكعبات سكر، حلويات، بسكويت أو عصير فاكهة يحتوي على السكر.</p><ul dir="rtl"><li>أعراض البرد مثل التهاب الحلق، أو احتقان الأنف</li><li>التهاب الجيوب الأنفية</li><li>حكة في الجلد</li><li>صداع</li><li>ألم في المعدة</li><li>إسهال</li><li>عسر في الهضم، حرقة</li><li>غثيان</li><li>ألم في العضلات</li><li>الشعور بتنميل في أي جزء من جسمك</li><li>عدم وضوح أو تشويش الرؤية</li><li>زيادة في الوزن</li><li>تورم اليدين أو القدمين</li><li>طفح جلدي</li></ul><p dir="RTL"><strong>غير شائعة:</strong></p><ul dir="rtl"><li>صعوبة في النوم</li></ul><p dir="RTL"><strong>غير معروفة:</strong></p><ul dir="rtl"><li>اضطرابات بصرية (ناتجة عن حالة تدعى الوذمة البقعية).</li><li>مشاكل في الكبد مثل الغثيان أو القيء، ألم في المعدة، تعب غير مفسر وغير اعتيادي، فقدان الشهية، بول غامق أو اصفرار جلدك أو بياض عينيك.</li></ul><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا يحفظ عند درجة حرارة أعلى من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الرطوبة.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. اتبع هذه الإجراءات للحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المواد الفعّالة هي بنزوات الألوغليبتين وهيدروكلوريد البيوغليتازون.</p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة من انكرسينك 25 ملغم/45 ملغم على 34 ملغم بنزوات الألوغليبتين تكافئ 25ملغم ألوغليبتين و49.59 ملغم هيدروكلوريد البيوغليتازون يكافئ 45 ملغم بيوغليتازون.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي: <em>لب القرص:</em> مانيتول، سيليلوز بلوري مكروي، هيدروكسي بروبيل السيليلوز، كروسكارميلوز الصوديوم، ستيارات المغنيسيوم ولاكتوز أحادي الماء. <em>الطبقة الرقیقة المغطیة:</em> هيبروميللوز، غليكول متعدد الإيثيلينن، ثنائي أكسيد التيتانيوم، تالك وأكسيد الحديد الأحمر. <em>حبر الطباعة:</em> F1 رمادي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">انكرسينك 25 ملغم/45 ملغم أقراص مغطاة بطبقة رقيقة هي أقراص مغطاة بطبقة رقيقة ذات لون أحمر، دائرية الشكل، محدبة الوجهين، مطبوع عليها &ldquo;A/P&rdquo; و&quot;25/45&quot; معاً على جهة واحدة معبأة في أشرطة من الألمينيوم.</p><p dir="RTL">حجم العبوة: 28 قرص مغطى بطبقة رقيقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق </strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 4980170 (11-966) +<br />فاكس:&nbsp; 4980187 (11-966) +<br />البريد الإلكتروني: medical@jpi.com.sa</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">شركة تاكيدا للصناعات الدوائية المحدودة</p><p dir="RTL">85-17، جوسونماتشي، 2-تشومي</p><p dir="RTL">أوساكا 532-8686، اليابان</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 10/2018، رقم النسخة: SA1.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Incresync 25 mg/45 mg Film-coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 34 mg alogliptin benzoate equivalent to 25 mg alogliptin and 49.59 mg pioglitazone hydrochloride equivalent to 45 mg pioglitazone.
Excipient with known effect: Each 25 mg/45 mg film-coated tablet contains 110.43 mg lactose monohydrate.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets.

Red round biconvex film-coated tablets, with both “A/P” and “25/45” printed on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Incresync is indicated as a second or third line treatment in adult patients aged 18 years and older with type 2 diabetes mellitus:</p><ul><li>&nbsp; &nbsp;As an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on pioglitazone alone, and for whom metformin is inappropriate due to contraindications or intolerance.</li><li>&nbsp; &nbsp; In combination with metformin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on their maximal tolerated dose of metformin and pioglitazone.</li></ul><p>In addition, Incresync can be used to replace separate tablets of alogliptin and pioglitazone in those adult patients aged 18 years and older with type 2 diabetes mellitus already being treated with this combination.</p><p>After initiation of therapy with Incresync, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, Incresync should be discontinued. In light of potential risks with prolonged pioglitazone therapy, prescribers should confirm at subsequent routine reviews that the benefit of Incresync is maintained (see section 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p>For the different dose regimens alogliptin/pioglitazone<strong> </strong>is available in strengths of 25 mg/15 mg, 25 mg/30 mg, 25 mg/45 mg, 12.5 mg/30 mg and 12.5 mg/45 mg film-coated tablets.</p><p><em><u>Adults (&ge; 18 years old)</u></em></p><p>The dose should be individualised on the basis of the patient&rsquo;s current treatment regimen</p><p>For patients intolerant to metformin or for whom metformin is contraindicated, inadequately controlled on pioglitazone alone, the recommended dose of Incresync is one tablet of 25 mg/15 mg, 25 mg/30 or 25 mg/45 mg once daily, depending on the dose of pioglitazone already being taken.</p><p>For patients inadequately controlled on dual therapy with pioglitazone and a maximally tolerated dose of metformin, the dose of metformin should be maintained, and Incresync administered concomitantly. The recommended dose is one tablet of 25 mg/15 mg, 25 mg/30 mg or 25 mg/45 mg once daily, depending on the dose of pioglitazone already being taken.</p><p>Caution should be exercised when alogliptin is used in combination with metformin and a thiazolidinedione as an increased risk of hypoglycaemia has been observed with this triple therapy (see section 4.4). In case of hypoglycaemia, a lower dose of the thiazolidinedione or metformin may be considered.</p><p>For patients switching from separate tablets of alogliptin and pioglitazone, both alogliptin and pioglitazone should be dosed at the daily dose already being taken.</p><p><em>Maximum daily dose</em></p><p>The maximum recommended daily dose of 25 mg alogliptin and 45 mg pioglitazone should not be exceeded.</p><p><em><u>Special populations</u></em></p><p><em>Elderly (&ge; 65 years old)</em></p><p>No dose adjustment is necessary based on age (see section 4.4). However, dosing of alogliptin should be conservative in patients with advanced age due to the potential for decreased renal function in this population.</p><p><em>Renal impairment</em></p><p>For patients with mild renal impairment (creatinine clearance (CrCl) &gt; 50 to &le; 80 mL/min), no dose adjustment of Incresync is necessary (see section 5.2).</p><p>For patients with moderate renal impairment (CrCl &ge; 30 to &le; 50 mL/min), one-half of the recommended dose of alogliptin should be administered. Therefore, one tablet of 12.5 mg/30 mg or 12.5 mg/45 mg once daily, depending on the dose of pioglitazone already being taken, is recommended in patients with moderate renal impairment (see section 5.2).</p><p>Incresync is not recommended for patients with severe renal impairment (CrCl &lt; 30 mL/min) or end-stage renal disease requiring dialysis.</p><p>Appropriate assessment of renal function is recommended prior to initiation of Incresync and periodically thereafter (see section 4.4).</p><p><em>Hepatic impairment</em></p><p>Incresync must not be used in patients with hepatic impairment (see sections 4.3, 4.4 and 5.2).</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Incresync in children and adolescents &lt; 18 years old have not been established. No data are available.</p><p><strong>Method of administration</strong></p><p>Oral use.</p><p>Incresync should be taken once daily with or without food. The tablets should be swallowed whole with water.</p><p>If a dose is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 or history of a serious hypersensitivity reaction, including anaphylactic reaction, anaphylactic shock, and angioedema, to any dipeptidyl-peptidase-4 (DPP-4) inhibitor (see sections 4.4 and 4.8)
•	Cardiac failure or history of cardiac failure (NYHA stages I to IV; see section 4.4)
•	Hepatic impairment (see section 4.4)
•	Diabetic ketoacidosis
•	Current bladder cancer or a history of bladder cancer (see section 4.4)
•	Uninvestigated macroscopic haematuria (see section 4.4)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>Incresync should not be used in patients with type 1 diabetes mellitus. Incresync is not a substitute for insulin in insulin-requiring patients.</p><p><u>Fluid retention and cardiac failure</u></p><p>Pioglitazone can cause fluid retention, which may exacerbate or precipitate heart failure. When treating patients who have at least one risk factor for development of congestive heart failure (e.g. prior myocardial infarction or symptomatic coronary artery disease or the elderly), physicians should start pioglitazone therapy with the lowest available dose and increase the dose gradually. Patients should be observed for signs and symptoms of heart failure, weight gain or oedema; particularly those with reduced cardiac reserve. There have been post-marketing cases of cardiac failure reported when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure. Patients should be observed for signs and symptoms of heart failure, weight gain and oedema when pioglitazone is used in combination with insulin. Since insulin and pioglitazone are both associated with fluid retention, concomitant administration may increase the risk of oedema. Post marketing cases of peripheral oedema and cardiac failure have also been reported in patients with concomitant use of pioglitazone and nonsteroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors. Incresync should be discontinued if any deterioration in cardiac status occurs.</p><p>A cardiovascular outcome study of pioglitazone has been performed in patients under 75 years with type 2 diabetes mellitus and pre-existing major macrovascular disease. Pioglitazone or placebo was added to existing anti-diabetic and cardiovascular therapy for up to 3.5 years. This study showed an increase in reports of heart failure, however this did not lead to an increase in mortality in this study.</p><p><u>Elderly patients</u></p><p>In light of age-related risks (especially bladder cancer, fractures and heart failure associated with the pioglitazone component), the balance of benefits and risks should be considered carefully both before and during Incresync treatment in the elderly.</p><p><u>Bladder cancer</u></p><p>Cases of bladder cancer were reported more frequently in a meta-analysis of controlled clinical studies with pioglitazone (19 cases from 12,506 patients, 0.15%) than in control groups (7 cases from 10,212 patients, 0.07%) HR=2.64 (95% CI 1.11-6.31, P=0.029). After excluding patients in whom exposure to the medicinal product was less than one year at the time of diagnosis of bladder cancer, there were 7 cases (0.06%) on pioglitazone and 2 cases (0.02%) in control groups. Epidemiological studies have also suggested a small increased risk of bladder cancer in diabetic patients treated with pioglitazone, although not all studies identified a statistically significant increased risk.</p><p>Risk factors for bladder cancer should be assessed before initiating Incresync treatment (risks include age, smoking history, exposure to some occupational or chemotherapy medicinal products e.g. cyclophosphamide or prior radiation treatment in the pelvic region). Any macroscopic haematuria should be investigated before starting therapy.</p><p>Patients should be advised to promptly seek the attention of their physician if macroscopic haematuria or other symptoms such as dysuria or urinary urgency develop during treatment.</p><p><u>Monitoring of liver function</u></p><p>There have been rare reports of hepatocellular dysfunction during post-marketing experience with pioglitazone (see section 4.8). Postmarketing reports of hepatic dysfunction including hepatic failure have been received for alogliptin. It is recommended, therefore, that patients treated with Incresync undergo periodic monitoring of liver enzymes. Liver enzymes should be checked prior to the initiation of therapy in all patients. Therapy with Incresync should not be initiated in patients with increased baseline liver enzyme levels (ALT &gt; 2.5 x upper limit of normal) or with any other evidence of liver disease.</p><p>Following initiation of therapy with Incresync, it is recommended that liver enzymes be monitored periodically based on clinical judgement. If ALT levels are increased to 3 x upper limit of normal during therapy, liver enzyme levels should be reassessed as soon as possible. If ALT levels remain &gt; 3 x the upper limit of normal, therapy should be discontinued. If any patient develops symptoms suggesting hepatic dysfunction, which may include unexplained nausea, vomiting, abdominal pain, fatigue, anorexia and/or dark urine, liver enzymes should be checked. The decision whether to continue the patient on therapy with Incresync should be guided by clinical judgement pending laboratory evaluations. If jaundice is observed, the medicinal product should be discontinued.</p><p><u>Renal impairment</u></p><p>As there is a need for dose adjustment of alogliptin in patients with moderate or severe renal impairment, or end-stage renal disease requiring dialysis, appropriate assessment of renal function is recommended prior to initiation of Incresync and periodically thereafter (see section 4.2).</p><p>Incresync is not recommended for patients with severe renal impairment or end-stage renal disease requiring dialysis. No information is available on pioglitazone and alogliptin use in dialysed patients and, therefore, co-administered alogliptin plus pioglitazone should not be used in such patients (see sections 4.2 and 5.2).</p><p><u>Weight gain</u></p><p>In clinical studies with pioglitazone, there was evidence of dose-related weight gain, which may be due to fat accumulation and, in some cases, associated with fluid retention. In some cases, weight increase may be a symptom of cardiac failure, therefore weight should be closely monitored. Part of the treatment of diabetes is dietary control. Patients should be advised to adhere strictly to a calorie-controlled diet.</p><p><u>Haematology</u></p><p>There was a small reduction in mean haemoglobin (4% relative reduction) and haematocrit (4.1% relative reduction) during therapy with pioglitazone, consistent with haemodilution. Similar changes were seen in metformin- (haemoglobin 3-4% and haematocrit 3.6-4.1% relative reductions) and to a lesser extent sulphonylurea- and insulin- (haemoglobin 1-2% and haematocrit 1-3.2% relative reductions) treated patients in comparative-controlled studies with pioglitazone.</p><p><u>Use with other antihyperglycaemic medicinal products and hypoglycaemia</u></p><p>Due to the increased risk of hypoglycaemia in combination with metformin, a lower dose of metformin or the pioglitazone component may be considered to reduce the risk of hypoglycaemia when this combination is used (see section 4.2).</p><p><u>Combinations not studied</u></p><p>The efficacy and safety of Incresync as triple therapy with a sulphonylurea has not been established and thus use is not recommended.</p><p>Incresync should not be used in combination with insulin, as the safety and efficacy of this combination have not been established.</p><p><u>Eye disorders</u></p><p>Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone. Many of these patients reported concurrent peripheral oedema. It is unclear whether or not there is a direct association between pioglitazone and macular oedema but prescribers should be alert to the possibility of macular oedema if patients on Incresync report disturbances in visual acuity; an appropriate ophthalmological referral should be considered.</p><p><u>Hypersensitivity reactions</u></p><p>Hypersensitivity reactions, including anaphylactic reactions, angioedema and exfoliative skin conditions including Stevens-Johnson syndrome and erythema multiforme have been observed for DPP-4 inhibitors and have been spontaneously reported for alogliptin in the post-marketing setting. In clinical studies of alogliptin, anaphylactic reactions were reported with a low incidence.</p><p><u>Acute pancreatitis</u></p><p>Use of DPP-4 inhibitors has been associated with a risk of developing acute pancreatitis. In a pooled analysis of the data from 13 studies, the overall rates of pancreatitis reports in patients treated with 25 mg alogliptin, 12.5 mg alogliptin, active control or placebo were 2, 1, 1 or 0 events per 1,000 patient years, respectively. In the cardiovascular outcomes study the rates of pancreatitis reports in patients treated with alogliptin or placebo were 3 or 2 events per 1,000 patient years, respectively. There have been spontaneously reported adverse reactions of acute pancreatitis in the post-marketing setting. Patients should be informed of the characteristic symptom of acute pancreatitis: persistent, severe abdominal pain, which may radiate to the back. If pancreatitis is suspected, Incresync should be discontinued; if acute pancreatitis is confirmed, Incresync should not be restarted. Caution should be exercised in patients with a history of pancreatitis.</p><p><u>Others</u></p><p>An increased incidence in bone fractures in women was seen in a pooled analysis of adverse reactions of bone fracture from randomised, controlled, double-blind clinical studies in over 8,100 pioglitazone and 7,400 comparator-treated patients, on treatment for up to 3.5 years.</p><p>Fractures were observed in 2.6% of women taking pioglitazone compared to 1.7% of women treated with a comparator. No increase in fracture rates was observed in men treated with pioglitazone (1.3%) versus comparator (1.5%).</p><p>The fracture incidence calculated was 1.9 fractures per 100 patient years in women treated with pioglitazone and 1.1 fractures per 100 patient years in women treated with a comparator. The observed excess risk of fractures for women in this dataset on pioglitazone is, therefore, 0.8 fractures per 100 patient years of use.</p><p>In the 3.5 year cardiovascular risk PROactive study, 44/870 (5.1%; 1.0 fractures per 100 patient years) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%; 0.5 fractures per 100 patient years) of female patients treated with comparator. No increase in fracture rates was observed in men treated with pioglitazone (1.7%) versus comparator (2.1%).</p><p>Some epidemiological studies have suggested a similarly increased risk of fracture in both men and women. The risk of fractures should be considered in the long-term care of patients treated with Incresync (see section 4.8).</p><p>As a consequence of enhancing insulin action, pioglitazone treatment in patients with polycystic ovarian syndrome may result in resumption of ovulation. These patients may be at risk of pregnancy. Patients should, therefore, be made aware of the risk of pregnancy and if a patient wishes to become pregnant or if pregnancy occurs, Incresync treatment should be discontinued (see section 4.6).</p><p>Incresync should be used with caution during concomitant administration of cytochrome P450 2C8 inhibitors (e.g. gemfibrozil) or inducers (e.g. rifampicin). Glycaemic control should be monitored closely. Pioglitazone dose adjustment within the recommended posology or changes in diabetic treatment should be considered (see section 4.5).</p><p><u>Incresync contains lactose monohydrate</u></p><p>Incresync contains lactose monohydrate. Each 25 mg/45 mg film-coated tablet contains 110.43 mg lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Co-administration of 25 mg alogliptin once daily and 45 mg pioglitazone once daily for 12 days in healthy subjects had no clinically relevant effects on the pharmacokinetics of alogliptin, pioglitazone or their active metabolites.</p><p>Specific pharmacokinetic drug interaction studies have not been performed with Incresync. The following section outlines the interactions observed with the individual components of Incresync (alogliptin/pioglitazone) as reported in their respective Summary of Product Characteristics.</p><p><u>Interactions with pioglitazone</u></p><p>Co-administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) is reported to result in a 3-fold increase in AUC for pioglitazone. Since there is a potential for an increase in dose-related adverse reactions, a decrease in the dose of pioglitazone may be needed when gemfibrozil is concomitantly administered. Close monitoring of glycaemic control should be considered (see section 4.4).</p><p>Co-administration of pioglitazone with rifampicin (an inducer of cytochrome P450 2C8) is reported to result in a 54% decrease in AUC for pioglitazone. The pioglitazone dose may need to be increased when rifampicin is concomitantly administered. Close monitoring of glycaemic control should be considered (see section 4.4).</p><p>Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon or metformin. Co-administration of pioglitazone with sulphonylureas does not appear to affect the pharmacokinetics of the sulphonylurea. Studies in man suggest no induction of the main inducible cytochrome P450, 1A, 2C8/9 and 3A4. In vitro studies have shown no inhibition of any subtype of cytochrome P450. Interactions with substances metabolised by these enzymes, e.g. oral contraceptives, cyclosporin, calcium channel blockers and HMGCoA reductase inhibitors, are not to be expected.</p><p><u>Effects of other medicinal products on alogliptin</u></p><p>Alogliptin is primarily excreted unchanged in the urine and metabolism by the cytochrome (CYP) P450 enzyme system is negligible (see section 5.2). Interactions with CYP inhibitors are thus not expected and have not been shown.</p><p>Results from clinical interaction studies also demonstrate that there are no clinically relevant effects of gemfibrozil (a CYP2C8/9 inhibitor), fluconazole (a CYP2C9 inhibitor), ketoconazole (a CYP3A4 inhibitor), cyclosporine (a p-glycoprotein inhibitor), voglibose (an alpha-glucosidase inhibitor), digoxin, metformin, cimetidine, pioglitazone or atorvastatin on the pharmacokinetics of alogliptin.</p><p><u>Effects of alogliptin on other medicinal products</u></p><p>In vitro studies suggest that alogliptin does not inhibit nor induce CYP 450 isoforms at concentrations achieved with the recommended dose of 25 mg alogliptin (see section 5.2). Interaction with substrates of CYP 450 isoforms are thus not expected and have not been shown. In studies in vitro, alogliptin was found to be neither a substrate nor an inhibitor of key transporters associated with disposition of the active substance in the kidney: organic anion transporter-1, organic anion transporter-3 or organic cationic transporter-2 (OCT2). Furthermore, clinical data do not suggest interaction with p-glycoprotein inhibitors or substrates.</p><p>In clinical studies, alogliptin had no clinically relevant effect on the pharmacokinetics of caffeine, (R)-warfarin, pioglitazone, glyburide, tolbutamide, (S)-warfarin, dextromethorphan, atorvastatin, midazolam, an oral contraceptive (norethindrone and ethinyl oestradiol), digoxin, fexofenadine, metformin, or cimetidine, thus providing in vivo evidence of a low propensity to cause interaction with substrates of CYP1A2, CYP3A4, CYP2D6, CYP2C9, p-glycoprotein, and OCT2.</p><p>In healthy subjects, alogliptin had no effect on prothrombin time or International Normalised Ratio (INR) when administered concomitantly with warfarin.</p><p><u>Combination of alogliptin with other anti-diabetic medicinal products</u></p><p>Results from alogliptin studies with metformin, pioglitazone (thiazolidinedione), voglibose (alpha-glucosidase inhibitor) and glyburide (sulphonylurea) have shown no clinically relevant pharmacokinetic interactions.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Pregnancy Category: C.</p><p>There are no data from the use of Incresync in pregnant women. Studies in animals with alogliptin plus pioglitazone as combination treatment have shown reproductive toxicity (slight augmentation of pioglitazone-related foetal growth retardation and foetal visceral variations, see section 5.3). Incresync should not be used during pregnancy.</p><p><em><u>Risk related to alogliptin</u></em></p><p>There are no data from the use of alogliptin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p><em><u>Risk related to pioglitazone</u></em></p><p>There are no adequate human data to determine the safety of pioglitazone during pregnancy. Foetal growth restriction was apparent in animal studies with pioglitazone. This was attributable to the action of pioglitazone in diminishing the maternal hyperinsulinaemia and increased insulin resistance that occurs during pregnancy, thereby reducing the availability of metabolic substrates for foetal growth. The relevance of such a mechanism in humans is unclear.</p><p><u>Breast-feeding</u></p><p>No studies in lactating animals have been conducted with the combined active substances of Incresync. In studies performed with the individual active substances, both alogliptin and pioglitazone were excreted in the milk of lactating rats. It is unknown whether alogliptin and pioglitazone are excreted in human milk. A risk to the suckling child cannot be excluded.</p><p>A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Incresync therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p><u>Fertility</u></p><p>The effect of Incresync on fertility in humans has not been studied. No adverse effects on fertility were observed in animal studies conducted with alogliptin (see section 5.3). In animal fertility studies conducted with pioglitazone there was no effect on copulation, impregnation or fertility index.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Incresync has no or negligible influence on the ability to drive and use machines. However, patients who experience visual disturbance should be cautious when driving or using machines. Patients should be alerted to the risk of hypoglycaemia when Incresync is used in combination with other anti-diabetic medicinal products known to cause hypoglycaemia.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Acute pancreatitis is a serious adverse reaction and is attributed to the alogliptin component of Incresync (see section 4.4). Hypersensitivity reactions, including Stevens-Johnson syndrome, anaphylactic reactions, and angioedema are serious and are attributed to the alogliptin component of Incresync (see section 4.4). Other reactions such as upper respiratory tract infections, sinusitis, headache, hypoglycaemia, nausea, weight increase and oedema may occur commonly (&ge; 1/100 to &lt; 1/10).</p><p>Clinical studies conducted to support the efficacy and safety of Incresync involved the co-administration of alogliptin and pioglitazone as separate tablets. However, the results of bioequivalence studies have demonstrated that Incresync film-coated tablets are bioequivalent to the corresponding doses of alogliptin and pioglitazone co-administered as separate tablets.</p><p>The information provided is based on a total of 3,504 patients with type 2 diabetes mellitus, including 1,908 patients treated with alogliptin and pioglitazone, who participated in 4 phase 3 double-blind, placebo- or active-controlled clinical studies. These studies evaluated the effects of co-administered alogliptin and pioglitazone on glycaemic control and their safety as initial combination therapy, as dual therapy in patients initially treated with pioglitazone alone (with or without metformin or a sulphonylurea), and as add-on therapy to metformin.</p><p><u>Tabulated list of adverse reactions</u></p><p>The adverse reactions are listed by system organ class and frequency. Frequencies are defined as very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from available data).</p><p>Table 1: Adverse reactions</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class Adverse reaction</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Frequency of adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Alogliptin</strong></p></td><td style="vertical-align:top"><p><strong>Pioglitazone</strong></p></td><td style="vertical-align:top"><p><strong>Incresync</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infections</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>nasopharyngitis</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>sinusitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Neoplasms benign, malignant and unspecified (including cysts and polyps)</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>bladder cancer</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>hypersensitivity</p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>hypersensitivity and allergic reactions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>hypoglycaemia</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>hypoaesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>insomnia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>visual disturbance</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>macular oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>abdominal pain</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>gastroesophageal reflux disease</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>diarrhoea</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>dyspepsia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>nausea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>acute pancreatitis</p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>hepatic dysfunction including hepatic failure</p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>pruritus</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>rash</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>exfoliative skin conditions including Stevens- Johnson syndrome</p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>erythema multiforme</p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>angioedema</p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>urticaria</p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissues disorders</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>fracture bone</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>oedema peripheral</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>weight increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>weight increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>alanine aminotransferase increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><u>Description of selected adverse reactions</u></p><p>Post-marketing spontaneous reports of hypersensitivity reactions in patients treated with pioglitazone include anaphylaxis, angioedema, and urticaria.</p><p>Visual disturbance has been reported mainly early in treatment and is related to changes in blood glucose due to temporary alteration in the turgidity and refractive index of the lens as seen with other hypoglycaemic treatments.</p><p>Oedema was reported in 6-9% of patients treated with pioglitazone over one year in controlled clinical studies. The oedema rates for comparator groups (sulphonylurea, metformin) were 2-5%. The reports of oedema were generally mild to moderate and usually did not require discontinuation of treatment.</p><p>A pooled analysis was conducted of adverse reactions of bone fractures from randomised, comparator-controlled, double-blind clinical studies in over 8,100 patients in the pioglitazone-treated groups and 7,400 in the comparator-treated groups of up to 3.5 years duration. A higher rate of fractures was observed in women taking pioglitazone (2.6%) versus comparator (1.7%). No increase in fracture rates was observed in men treated with pioglitazone (1.3%) versus comparator (1.5%). In the 3.5 year PROactive study, 44/870 (5.1%) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%) of female patients treated with comparator. No increase in fracture rates was observed in men treated with pioglitazone (1.7%) versus comparator (2.1%). Post-marketing, bone fractures have been reported in both male and female patients (see section 4.4).</p><p>In active comparator-controlled studies, mean weight increase with pioglitazone given as monotherapy was 2-3 kg over one year. This is similar to that seen in a sulphonylurea active comparator group. In combination studies, pioglitazone added to metformin resulted in mean weight increase over one year of 1.5 kg and added to a sulphonylurea of 2.8 kg. In comparator groups, addition of sulphonylurea to metformin resulted in a mean weight gain of 1.3 kg and addition of metformin to a sulphonylurea a mean weight loss of 1.0 kg.</p><p>In clinical studies with pioglitazone, the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo but less than that seen in metformin or sulphonylurea comparator groups. Mean levels of liver enzymes decreased with treatment with pioglitazone. Rare cases of elevated liver enzymes and hepatocellular dysfunction have occurred in post-marketing experience. Although in very rare cases, fatal outcome has been reported, causal relationship has not been established.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>&nbsp;Saudi Arabia</li></ul><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: + (966-11) 2057662</p><p>Toll free: 800-249-0000</p><p>Phone No.: + (966-11) 2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>e-mail: npc.drug@sfda.gov.sa</p><p>Website: <u>www.sfda.gov.sa/npc</u></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No data are available with regard to overdose of Incresync.</p><p><u>Alogliptin</u></p><p>The highest doses of alogliptin administered in clinical studies were single doses of 800 mg to healthy subjects and doses of 400 mg once daily for 14 days to patients with type 2 diabetes mellitus (equivalent to 32 times and 16 times the recommended daily dose of 25 mg alogliptin, respectively).</p><p><u>Pioglitazone</u></p><p>In clinical studies, patients have taken pioglitazone at higher than the recommended highest dose of 45 mg daily. The maximum reported dose of 120 mg/day for four days, then 180 mg/day for seven days was not associated with any symptoms.</p><p>Hypoglycaemia may occur in combination with sulphonylureas or insulin.</p><p><u>Management</u></p><p>In the event of an overdose, appropriate supportive measures should be employed as dictated by the patient&rsquo;s clinical status.</p><p>Minimal quantities of alogliptin are removed by haemodialysis (approximately 7% of the substance was removed during a 3-hour haemodialysis session). Therefore, haemodialysis is of little clinical benefit in overdose. It is not known if alogliptin is removed by peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes; combinations of oral blood glucose lowering drugs.</p><p>ATC code: A10BD09.</p><p><u>Mechanism of action and pharmacodynamic effects</u></p><p>Incresync combines two antihyperglycaemic medicinal products with complementary and distinct mechanisms of action to improve glycaemic control in patients with type 2 diabetes mellitus: alogliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor, and pioglitazone, a member of the thiazolidinedione class. Studies in animal models of diabetes showed that concomitant treatment with alogliptin and pioglitazone produced both additive and synergistic improvements in glycaemic control, increased pancreatic insulin content and normalised pancreatic beta-cell distribution.</p><p><em><u>Alogliptin</u></em></p><p>Alogliptin is a potent and highly selective inhibitor of DPP-4, &gt;10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9. DPP-4 is the principal enzyme involved in the rapid degradation of the incretin hormones, glucagon-like peptide-1 (GLP-1) and GIP (glucose dependent insulinotropic polypeptide), which are released by the intestine and levels are increased in response to a meal. GLP-1 and GIP increases insulin biosynthesis and secretion from pancreatic beta cells, while GLP-1 also inhibits glucagon secretion and hepatic glucose production. Alogliptin therefore improves glycaemic control via a glucose-dependent mechanism, whereby insulin release is enhanced and glucagon levels are suppressed when glucose levels are high.</p><p><u>Pioglitazone</u></p><p>Pioglitazone effects may be mediated by a reduction of insulin resistance. Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals. Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance.</p><p>Fasting and postprandial glycaemic control is improved following treatment with pioglitazone in patients with type 2 diabetes mellitus. The improved glycaemic control is associated with a reduction in both fasting and postprandial plasma insulin concentrations.</p><p>HOMA analysis shows that pioglitazone improves beta-cell function as well as increasing insulin sensitivity. Two-year clinical studies have shown maintenance of this effect.</p><p>In one-year clinical studies, pioglitazone consistently gave a statistically significant reduction in the albumin/creatinine ratio compared to baseline.</p><p>The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week study in type 2 diabetics. Pioglitazone was associated with significant weight gain. Visceral fat was significantly decreased while there was an increase in extra-abdominal fat mass. Similar changes in body fat distribution on pioglitazone have been accompanied by an improvement in insulin sensitivity. In most clinical studies, reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels were observed as compared to placebo with small, but not clinically significant, increases in LDL-cholesterol levels.</p><p>In clinical studies of up to two years duration, pioglitazone reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels compared to placebo, metformin or gliclazide. Pioglitazone did not cause statistically significant increases in LDL-cholesterol levels compared to placebo whilst reductions were observed with metformin and gliclazide. In a 20-week study, as well as reducing fasting triglycerides, pioglitazone reduced postprandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides. These effects were independent of pioglitazone&rsquo;s effects on glycaemia and were statistically significantly different to glibenclamide.</p><p><u>Clinical efficacy</u></p><p>Clinical studies conducted to support the efficacy of Incresync involved the co-administration of alogliptin and pioglitazone as separate tablets. However, the results of bioequivalence studies have demonstrated that Incresync film-coated tablets are bioequivalent to the corresponding doses of alogliptin and pioglitazone co-administered as separate tablets.</p><p>The co-administration of alogliptin and pioglitazone has been studied as dual therapy in patients initially treated with pioglitazone alone (with or without metformin or a sulphonylurea) and as add-on therapy to metformin.</p><p>Administration of 25 mg alogliptin to patients with type 2 diabetes mellitus produced peak inhibition of DPP-4 within 1 to 2 hours and exceeded 93% both after a single 25 mg dose and after 14 days of once-daily dosing. Inhibition of DPP-4 remained above 81% at 24 hours after 14 days of dosing. When the 4-hour postprandial glucose concentrations were averaged across breakfast, lunch and dinner, 14 days of treatment with 25 mg alogliptin resulted in a mean placebo-corrected reduction from baseline of -35.2 mg/dL.</p><p>Both 25 mg alogliptin alone and in combination with 30 mg pioglitazone demonstrated significant decreases in postprandial glucose and postprandial glucagon whilst significantly increasing postprandial active GLP-1 levels at Week 16 compared to placebo (p&lt;0.05). In addition, 25 mg alogliptin alone and in combination with 30 mg pioglitazone produced statistically significant (p&lt;0.001) reductions in total triglycerides at Week 16 as measured by postprandial incremental AUC<sub>(0-8)</sub> change from baseline compared to placebo.</p><p>A total of 3,504 patients with type 2 diabetes mellitus, including 1,908 patients treated with alogliptin and pioglitazone, participated in 4 phase 3 double-blind, placebo- or active-controlled clinical studies conducted to evaluate the effects of co-administered alogliptin and pioglitazone on glycaemic control and their safety. In these studies, 312 alogliptin/pioglitazone-treated patients were &ge; 65 years old. The studies included 1,269 patients with mild renal impairment and 161 patients with moderate renal impairment treated with alogliptin/pioglitazone.</p><p>Overall, treatment with the recommended daily dose of 25 mg alogliptin in combination with pioglitazone improved glycaemic control. This was determined by clinically relevant and statistically significant reductions in glycosylated haemoglobin (HbA1c) and fasting plasma glucose compared to control from baseline to study endpoint. Reductions in HbA1c were similar across different subgroups including renal impairment, age, gender and body mass index, while differences between races (e.g. White and non-White) were small. Clinically meaningful reductions in HbA1c compared to control were also observed regardless of baseline background medicinal product dose. Higher baseline HbA1c was associated with a greater reduction in HbA1c. Generally, the effects of alogliptin on body weight and lipids were neutral.</p><p><em><u>Alogliptin as add-on therapy to pioglitazone</u></em></p><p>The addition of 25 mg alogliptin once daily to pioglitazone therapy (mean dose = 35.0 mg, with or without metformin or a sulphonylurea) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 2). Clinically meaningful reductions in HbA1c compared to placebo were also observed with 25 mg alogliptin regardless of whether patients were receiving concomitant metformin or sulphonylurea therapy. Significantly more patients receiving 25 mg alogliptin (49.2%) achieved target HbA1c levels of &le; 7.0% compared to those receiving placebo (34.0%) at Week 26 (p=0.004).</p><p><em><u>Alogliptin as add-on therapy to pioglitazone with metformin</u></em></p><p>The addition of 25 mg alogliptin once daily to 30 mg pioglitazone in combination with metformin</p><p>hydrochloride therapy (mean dose = 1,867.9 mg) resulted in improvements from baseline in HbA1c at Week 52 that were both non-inferior and statistically superior to those produced by 45 mg pioglitazone in combination with metformin hydrochloride therapy (mean dose = 1,847.6 mg, Table 3). The significant reductions in HbA1c observed with 25 mg alogliptin plus 30 mg pioglitazone and metformin were consistent over the entire 52-week treatment period compared to 45 mg pioglitazone and metformin (p&lt;0.001 at all time points). In addition, mean change from baseline in fasting plasma glucose at Week 52 for 25 mg alogliptin plus 30 mg pioglitazone and metformin was significantly greater than that for 45 mg pioglitazone and metformin (p&lt;0.001). Significantly more patients receiving 25 mg alogliptin plus 30 mg pioglitazone and metformin (33.2%) achieved target HbA1c levels of &le; 7.0% compared to those receiving 45 mg pioglitazone and metformin (21.3%) at Week 52 (p&lt;0.001).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 2: Change in HbA1c (%) from baseline with alogliptin 25 mg at Week 26 by placebo-controlled study (FAS, LOCF)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Study</strong></p></td><td style="vertical-align:top"><p><strong>Mean baseline HbA1c (%) (SD)</strong></p></td><td style="vertical-align:top"><p><strong>Mean change from baseline in HbA1c (%)&dagger; (SE)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo-corrected change from baseline in HbA1c (%)<sup>&dagger;</sup> (2-sided 95% CI)</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Add-on combination therapy placebo-controlled studies</em></p></td></tr><tr><td style="vertical-align:top"><p>Alogliptin 25 mg once daily with pioglitazone &plusmn; metformin or a sulphonylurea (n=195)</p></td><td style="vertical-align:top"><p>8.01</p><p>(0.837)</p></td><td style="vertical-align:top"><p>-0.80</p><p>(0.056)</p></td><td style="vertical-align:top"><p>-0.61<sup>*</sup></p><p>(-0.80, -0.41)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>FAS = full analysis set</p><p>LOCF = last observation carried forward</p><p>&dagger; Least squares means adjusted for prior antihyperglycaemic therapy status and baseline values</p><p>* p&lt;0.001 compared to placebo or placebo+combination treatment</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 3: Change in HbA1c (%) from baseline with alogliptin 25 mg by active-controlled study (PPS, LOCF)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Study</strong></p></td><td style="vertical-align:top"><p><strong>Mean baseline HbA1c (%) (SD)</strong></p></td><td style="vertical-align:top"><p><strong>Mean change from baseline in HbA1c (%)&dagger; (SE)</strong></p></td><td style="vertical-align:top"><p><strong>Treatment-corrected change from baseline in HbA1c (%)&dagger; (1-sided CI)</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Add-on combination therapy studies</em></p></td></tr><tr><td style="vertical-align:top"><p>Alogliptin 25 mg once daily with pioglitazone + metformin vs titrating pioglitazone + metformin</p><p>&nbsp;</p><p>Change at Week 26 (n=303)</p><p>&nbsp;</p><p>&nbsp;</p><p>Change at Week 52 (n=303)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>8.25</p><p>(0.820)</p><p>&nbsp;</p><p>8.25</p><p>(0.820)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>-0.89</p><p>(0.042)</p><p>&nbsp;</p><p>-0.70</p><p>(0.048)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>-0.47*</p><p>(-infinity, -0.35)</p><p>&nbsp;</p><p>-0.42*</p><p>(-infinity, -0.28)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>PPS = per protocol set</p><p>LOCF = last observation carried forward</p><p>* Non inferiority and superiority statistically demonstrated</p><p>&dagger; Least squares means adjusted for prior antihyperglycaemic therapy status and baseline values</p></td></tr></tbody></table><p><em><u>Patients with renal impairment</u></em></p><p>Incresync is not recommended for patients with severe renal impairment or end-stage renal disease requiring dialysis (see section 4.2).</p><p><em><u>Elderly (&ge; 65 years old)</u></em></p><p>The efficacy and safety of the recommended doses of alogliptin and pioglitazone in a subgroup of patients with type 2 diabetes mellitus and &ge; 65 years old were reviewed and found to be consistent with the profile obtained in patients &lt; 65 years old.</p><p><u>Clinical safety</u></p><p><em><u>Cardiovascular Safety</u></em></p><p>In a pooled analysis of the data from 13 studies, the overall incidences of cardiovascular death, non fatal myocardial infarction and non-fatal stroke were comparable in patients treated with 25 mg alogliptin, active control or placebo.</p><p>In addition, a prospective randomised cardiovascular outcomes safety study was conducted with 5,380 patients with high underlying cardiovascular risk to examine the effect of alogliptin compared with placebo (when added to standard of care) on major adverse cardiovascular events (MACE) including time to the first occurrence of any event in the composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke in patients with a recent (15 to 90 days) acute coronary event. At baseline, patients had a mean age of 61 years, mean duration of diabetes of 9.2 years, and mean HbA1c of 8.0%.</p><p>The study demonstrated that alogliptin did not increase the risk of having a MACE compared to placebo [Hazard Ratio: 0.96; 1-sided 99% Confidence Interval: 0-1.16]. In the alogliptin group, 11.3% of patients experienced a MACE compared to 11.8% of patients in the placebo group.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 4. MACE Reported in cardiovascular outcomes study</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Number of Patients (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Alogliptin 25 mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p>N=2,701</p></td><td style="vertical-align:top"><p>N=2,679</p></td></tr><tr><td style="vertical-align:top"><p><strong>Primary Composite Endpoint [First Event of CV Death, Nonfatal MI and Nonfatal Stroke]</strong></p></td><td style="vertical-align:top"><p><strong>305 (11.3)</strong></p></td><td style="vertical-align:top"><p><strong>316 (11.8)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cardiovascular Death*</p></td><td style="vertical-align:top"><p>89 (3.3)</p></td><td style="vertical-align:top"><p>111 (4.1)</p></td></tr><tr><td style="vertical-align:top"><p>Nonfatal Myocardial Infarction</p></td><td style="vertical-align:top"><p>187 (6.9)</p></td><td style="vertical-align:top"><p>173 (6.5)</p></td></tr><tr><td style="vertical-align:top"><p>Nonfatal Stroke</p></td><td style="vertical-align:top"><p>29 (1.1)</p></td><td style="vertical-align:top"><p>32 (1.2)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*Overall there were 153 subjects (5.7%) in the alogliptin group and 173 subjects (6.5%) in the placebo group who died (all-cause mortality)</p></td></tr></tbody></table><p>There were 703 patients who experienced an event within the secondary MACE composite endpoint (first event of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke and urgent revascularization due to unstable angina). In the alogliptin group, 12.7% (344 subjects) experienced an event within the secondary MACE composite endpoint, compared with 13.4% (359 subjects) in the placebo group [Hazard Ratio = 0.95; 1-sided 99% Confidence Interval: 0-1.14].</p><p>In controlled clinical studies, the incidence of reports of heart failure with pioglitazone treatment was the same as in placebo, metformin and sulphonylurea treatment groups, but was increased when used in combination therapy with insulin. In an outcome study of patients with pre-existing major macrovascular disease, the incidence of serious heart failure was 1.6% higher with pioglitazone than with placebo when added to therapy that included insulin. However, this did not lead to an increase in mortality in this study. Heart failure has been reported rarely with marketing use of pioglitazone, but more frequently when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure.</p><p>In PROactive, a cardiovascular outcome study, 5,238 patients with type 2 diabetes mellitus and pre-existing major macrovascular disease were randomised to pioglitazone or placebo in addition to existing anti-diabetic and cardiovascular therapy, for up to 3.5 years. The study population had an average age of 62 years; the average duration of diabetes was 9.5 years. Approximately one third of patients were receiving insulin in combination with metformin and/or a sulphonylurea. To be eligible, patients had to have had one or more of the following: myocardial infarction, stroke, percutaneous cardiac intervention or coronary artery bypass graft, acute coronary syndrome, coronary artery disease, or peripheral arterial obstructive disease. Almost half of the patients had a previous myocardial infarction and approximately 20% had had a stroke. Approximately half of the study population had at least two of the cardiovascular history entry criteria. Almost all subjects (95%) were receiving cardiovascular medicinal products (beta blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II antagonists, calcium channel blockers, nitrates, diuretics, aspirin, statins, fibrates).</p><p>Although the study failed regarding its primary endpoint, which was a composite of all-cause mortality, non-fatal myocardial infarction, stroke, acute coronary syndrome, major leg amputation, coronary revascularisation and leg revascularisation, the results suggest that there are no long-term cardiovascular concerns regarding use of pioglitazone. However, the incidences of oedema, weight gain and heart failure were increased. No increase in mortality from heart failure was observed.</p><p><em><u>Hypoglycaemia</u></em></p><p>In a pooled analysis of the data from 12 studies, the overall incidence of any episode of hypoglycaemia was lower in patients treated with 25 mg alogliptin than in patients treated with 12.5 mg alogliptin, active-control or placebo (3.6%, 4.6%, 12.9% and 6.2%, respectively). The majority of these episodes were mild to moderate in intensity. The overall incidence of episodes of severe hypoglycaemia was comparable in patients treated with 25 mg alogliptin or 12.5 mg alogliptin, and lower than the incidence in patients treated with active-control or placebo (0.1%, 0.1%, 0.4% and 0.4%, respectively). In the prospective randomised controlled cardiovascular outcomes study, investigator reported events of hypoglycemia were similar in patients receiving placebo (6.5%) and patients receiving alogliptin (6.7%) in addition to standard of care.</p><p>A clinical study of alogliptin as add-on therapy to pioglitazone demonstrated that there was no clinically relevant increase in hypoglycaemia rate compared to placebo. The incidence of hypoglycaemia was greater when alogliptin was used as triple therapy with pioglitazone and metformin (compared to active-control). This has also been observed with other DPP-4 inhibitors.</p><p>Patients (&ge; 65 years old) with type 2 diabetes mellitus are considered more susceptible to episodes of hypoglycaemia than patients &lt; 65 years old. In a pooled analysis of the data from 12 studies, the overall incidence of any episode of hypoglycaemia was similar in patients &ge; 65 years old treated with 25 mg alogliptin (3.8%) to that in patients &lt; 65 years old (3.6%).</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Incresync in all subsets of the paediatric population in the treatment of type 2 diabetes mellitus (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The results of bioequivalence studies in healthy subjects demonstrated that Incresync film-coated tablets are bioequivalent to the corresponding doses of alogliptin and pioglitazone co-administered as separate tablets.</p><p>Co-administration of 25 mg alogliptin once daily and 45 mg pioglitazone once daily for 12 days in healthy subjects had no clinically relevant effects on the pharmacokinetics of alogliptin, pioglitazone or their active metabolites.</p><p>Administration of Incresync with food resulted in no change in overall exposure to alogliptin or pioglitazone. Incresync may, therefore, be administered with or without food.</p><p>The following section outlines the pharmacokinetic properties of the individual components of Incresync (alogliptin/pioglitazone) as reported in their respective Summary of Product Characteristics.</p><p><strong>Alogliptin</strong></p><p>The pharmacokinetics of alogliptin has been shown to be similar in healthy subjects and in patients with type 2 diabetes mellitus.</p><p><em><u>Absorption</u></em></p><p>The absolute bioavailability of alogliptin is approximately 100%.</p><p>Administration with a high-fat meal resulted in no change in total and peak exposure to alogliptin. Alogliptin may, therefore, be administered with or without food.</p><p>After administration of single, oral doses of up to 800 mg in healthy subjects, alogliptin was rapidly absorbed with peak plasma concentrations occurring 1 to 2 hours (median T<sub>max</sub>) after dosing.</p><p>No clinically relevant accumulation after multiple dosing was observed in either healthy subjects or in patients with type 2 diabetes mellitus.</p><p>Total and peak exposure to alogliptin increased proportionately across single doses of 6.25 mg up to 100 mg alogliptin (covering the therapeutic dose range). The inter-subject coefficient of variation for alogliptin AUC was small (17%).</p><p><em><u>Distribution</u></em></p><p>Following a single intravenous dose of 12.5 mg alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L indicating that the active substance is well distributed into tissues.</p><p>Alogliptin is 20-30% bound to plasma proteins.</p><p><em><u>Biotransformation</u></em></p><p>Alogliptin does not undergo extensive metabolism, 60-70% of the dose is excreted as unchanged active substance in the urine.</p><p>Two minor metabolites were detected following administration of an oral dose of [14C] alogliptin, N-demethylated alogliptin, M-I (&lt; 1% of the parent compound), and N-acetylated alogliptin, M-II (&lt; 6% of the parent compound). M-I is an active metabolite and is a highly selective inhibitor of DPP-4 similar to alogliptin; M-II does not display any inhibitory activity towards DPP-4 or other DPP-related enzymes. In vitro data indicate that CYP2D6 and CYP3A4 contribute to the limited metabolism of alogliptin.</p><p>In vitro studies indicate that alogliptin does not induce CYP1A2, CYP2B6 and CYP2C9 and does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4 at concentrations achieved with the recommended dose of 25 mg alogliptin. Studies in vitro have shown alogliptin to be a mild inducer of CYP3A4, but alogliptin has not been shown to induce CYP3A4 in studies in vivo.</p><p>In studies in vitro, alogliptin was not an inhibitor of the following renal transporters; OAT1, OAT3 and OCT2.</p><p>Alogliptin exists predominantly as the (R)-enantiomer (&gt; 99%) and undergoes little or no chiral conversion in vivo to the (S)-enantiomer. The (S)-enantiomer is not detectable at therapeutic doses.</p><p><em><u>Elimination</u></em></p><p>Alogliptin was eliminated with a mean terminal half-life (T<sup>1/2</sup>) of approximately 21 hours.</p><p>Following administration of an oral dose of [14C] alogliptin, 76% of total radioactivity was eliminated in the urine and 13% was recovered in the faeces.</p><p>The average renal clearance of alogliptin (170 mL/min) was greater than the average estimated glomerular filtration rate (approx. 120 mL/min), suggesting some active renal excretion.</p><p><em><u>Time-dependency</u></em></p><p>Total exposure (AUC<sub>(0-inf)</sub>) to alogliptin following administration of a single dose was similar to exposure during one dose interval (AUC<sub>(0-24)</sub>) after 6 days of once daily dosing. This indicates no time-dependency in the kinetics of alogliptin after multiple dosing.</p><p><em><u>Special populations</u></em></p><p><em>Renal impairment</em></p><p>A single dose of 50 mg alogliptin was administered to 4 groups of patients with varying degrees of renal impairment (CrCl using the Cockcroft-Gault formula): mild (CrCl = &gt; 50 to &le; 80 mL/min), moderate (CrCl = &ge; 30 to &le; 50 mL/min), severe (CrCl = &lt; 30 mL/min) and end-stage renal disease on haemodialysis.</p><p>An approximate 1.7-fold increase in AUC for alogliptin was observed in patients with mild renal impairment. However, as the distribution of AUC values for alogliptin in these patients was within the same range as control subjects, no dose adjustment of alogliptin for patients with mild renal impairment is necessary (see section 4.2).</p><p>In patients with moderate or severe renal impairment, or end-stage renal disease on haemodialysis, an increase in systemic exposure to alogliptin of approximately 2- and 4-fold was observed, respectively. (Patients with end-stage renal disease underwent haemodialysis immediately after alogliptin dosing. Based on mean dialysate concentrations, approximately 7% of the active substance was removed during a 3-hour haemodialysis session. Therefore, in order to maintain systemic exposures to alogliptin that are similar to those observed in patients with normal renal function, lower doses of alogliptin should be used in patients with moderate or severe renal impairment, or end-stage renal disease requiring dialysis (see above and section 4.2).</p><p><em>Hepatic impairment</em></p><p>Total exposure to alogliptin was approximately 10% lower and peak exposure was approximately 8% lower in patients with moderate hepatic impairment compared to control subjects. The magnitude of these reductions was not considered to be clinically relevant. Therefore, no dose adjustment of alogliptin is necessary for patients with mild to moderate hepatic impairment (Child-Pugh scores of 5 to 9). Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh score &gt; 9).</p><p><em>Age, gender, race, body weight</em></p><p>Age (65-81 years old), gender, race (white, black and Asian) and body weight did not have any clinically relevant effect on the pharmacokinetics of alogliptin. No dose adjustment is necessary (see section 4.2).</p><p><em>Paediatric population</em></p><p>The pharmacokinetics of alogliptin in children and adolescents &lt; 18 years old has not been established. No data are available (see section 4.2).</p><p><strong><u>Pioglitazone</u></strong></p><p><em><u>Absorption</u></em></p><p>Following oral administration, pioglitazone is rapidly absorbed and peak serum concentrations of unchanged pioglitazone are usually achieved 2 hours after administration. Proportional increases of the serum concentration were observed for doses from 2-60 mg. Steady-state is achieved after 4-7 days of dosing. Repeated dosing does not result in accumulation of the compound or metabolites. Absorption is not influenced by food intake. Absolute bioavailability is greater than 80%.</p><p><em><u>Distribution</u></em></p><p>The estimated volume of distribution in humans is 19 L.</p><p>Pioglitazone and all active metabolites are extensively bound to plasma protein (&gt; 99%).</p><p><em><u>Biotransformation</u></em></p><p>Pioglitazone undergoes extensive hepatic metabolism by hydroxylation of aliphatic methylene groups. This is predominantly via cytochrome P450 2C8 although other isoforms may be involved to a lesser degree. Three of the six identified pioglitazone metabolites are active (M-II, M-III, and M-IV). When activity, concentrations and protein binding are taken into account, pioglitazone and metabolite M-III contribute equally to efficacy. On this basis, M-IV contribution to efficacy is approximately 3-fold that of pioglitazone whilst the relative efficacy of M-II is minimal.</p><p>In vitro studies have shown no evidence that pioglitazone inhibits any subtype of cytochrome P450. There is no induction of the main inducible P450 isoenzymes 1A, 2C8/9 and 3A4 in man.</p><p>Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon or metformin. Concomitant administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) or with rifampicin (an inducer of cytochrome P450 2C8) is reported to increase or decrease, respectively, the serum concentration of pioglitazone (see section 4.5).</p><p><em><u>Elimination</u></em></p><p>Following oral administration of radiolabelled pioglitazone to man, recovered label was mainly in faeces (55%) and a lesser amount in urine (45%). In animals, only a small amount of unchanged pioglitazone can be detected in either urine or faeces. The mean serum elimination half-life of unchanged pioglitazone in man is 5 to 6 hours and for its total active metabolites 16 to 23 hours.</p><p><em><u>Special populations</u></em></p><p><em>Renal impairment</em></p><p>In patients with renal impairment, serum concentrations of pioglitazone and its metabolites are lower than those seen in subjects with normal renal function, but oral clearance of parent substance is similar. Thus, free (unbound) pioglitazone concentration is unchanged (see section 4.2).</p><p><em>Hepatic impairment</em></p><p>Total serum concentration of pioglitazone is unchanged, but with an increased volume of distribution. Intrinsic clearance is, therefore, reduced coupled with a higher unbound fraction of pioglitazone (see section 4.2).</p><p><em>Elderly (&ge; 65 years old)</em></p><p>Steady-state pharmacokinetics is similar in patients aged 65 years and over and young subjects (see section 4.2).</p><p><em>Paediatric population</em></p><p>The pharmacokinetics of pioglitazone in children and adolescents &lt; 18 years old has not been established. No data are available (see section 4.2).</p><p><strong>Incresync</strong></p><p><em><u>Special populations</u></em></p><p><em>Renal impairment</em></p><p>For patients with moderate renal impairment, alogliptin/pioglitazone<strong> </strong>12.5 mg/30 mg or 12.5 mg/45 mg should be administered once daily. Incresync is not recommended for patients with severe renal impairment or end-stage renal disease requiring dialysis. No dose adjustment of Incresync for patients with mild renal impairment is necessary (see section 4.2).</p><p><em>Hepatic impairment </em></p><p>Due to its pioglitazone component, Incresync should not be used in patients with hepatic impairment (see section 4.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal studies of up to 13-weeks duration have been conducted with the combined substances in Incresync.</p><p>Concomitant treatment with alogliptin and pioglitazone did not produce new toxicities, nor did it exacerbate any pioglitazone-related findings. No effects on the toxicokinetics of either compound were observed.</p><p>Combination treatment with alogliptin and pioglitazone to pregnant rats slightly augmented pioglitazone-related foetal effects of growth retardation and visceral variations, but did not induce embryo-foetal mortality or teratogenicity.</p><p>The following data are findings from studies performed with alogliptin or pioglitazone individually.</p><p><strong>Alogliptin</strong></p><p>Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and toxicology.</p><p>The no-observed-adverse-effect level (NOAEL) in the repeated dose toxicity studies in rats and dogs up to 26- and 39-weeks in duration, respectively, produced exposure margins that were approximately 147- and 227-fold, respectively, the exposure in humans at the recommended daily dose of 25 mg alogliptin.</p><p>Alogliptin was not genotoxic in a standard battery of in vitro and in vivo genotoxicity studies.</p><p>Alogliptin was not carcinogenic in 2-year carcinogenicity studies conducted in rats and mice. Minimal to mild simple transitional cell hyperplasia was seen in the urinary bladder of male rats at the lowest dose used (27 times the human exposure) without establishment of a clear NOEL (no observed effect level).</p><p>No adverse effects of alogliptin were observed upon fertility, reproductive performance, or early embryonic development in rats up to a systemic exposure far above the human exposure at the recommended dose. Although fertility was not affected, a slight, statistical increase in the number of abnormal sperm was observed in males at an exposure far above the human exposure at the recommended dose.</p><p>Placental transfer of alogliptin occurs in rats.</p><p>Alogliptin was not teratogenic in rats or rabbits with a systemic exposure at the NOAELs far above the human exposure at the recommended dose. Higher doses of alogliptin were not teratogenic but resulted in maternal toxicity, and were associated with delayed and/or lack of ossification of bones and decreased foetal body weights.</p><p>In a pre- and postnatal development study in rats, exposures far above the human exposure at the recommended dose did not harm the developing embryo or affect offspring growth and development. Higher doses of alogliptin decreased offspring body weight and exerted some developmental effects considered secondary to the low body weight.</p><p>Studies in lactating rats indicate that alogliptin is excreted in milk.</p><p>No alogliptin-related effects were observed in juvenile rats following repeat-dose administration for 4 and 8 weeks.</p><p><strong>Pioglitazone</strong></p><p>In toxicology studies, plasma volume expansion with haemodilution, anaemia and reversible eccentric cardiac hypertrophy was consistently apparent after repeated dosing of mice, rats, dogs and monkeys. In addition, increased fatty deposition and infiltration were observed. These findings were observed across species at plasma concentrations &le; 4 times the clinical exposure. Foetal growth restriction was apparent in animal studies with pioglitazone. This was attributable to the action of pioglitazone in diminishing the maternal hyperinsulinaemia and increased insulin resistance that occurs during pregnancy thereby reducing the availability of metabolic substrates for foetal growth.</p><p>Pioglitazone was devoid of genotoxic potential in a comprehensive battery of in vivo and in vitro genotoxicity assays. An increased incidence of hyperplasia (males and females) and tumours (males) of the urinary bladder epithelium was apparent in rats treated with pioglitazone for up to 2 years.</p><p>The formation and presence of urinary calculi with subsequent irritation and hyperplasia was postulated as the mechanistic basis for the observed tumourigenic response in the male rat. A 24-month mechanistic study in male rats demonstrated that administration of pioglitazone resulted in an increased incidence of hyperplastic changes in the bladder. Dietary acidification significantly decreased but did not abolish the incidence of tumours. The presence of microcrystals exacerbated the hyperplastic response but was not considered to be the primary cause of hyperplastic changes. The relevance to humans of the tumourigenic findings in the male rat cannot be excluded.</p><p>There was no tumourigenic response in mice of either sex. Hyperplasia of the urinary bladder was not seen in dogs or monkeys treated with pioglitazone for up to 12 months.</p><p>In an animal model of familial adenomatous polyposis, treatment with two other thiazolidinediones increased tumour multiplicity in the colon. The relevance of this finding is unknown.</p><p><strong>Environmental Risk Assessment (ERA)</strong></p><p>No environmental impact is anticipated from the clinical use of pioglitazone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core:</p><p>-&nbsp; Mannitol</p><p>-&nbsp;&nbsp;Microcrystalline cellulose</p><p>-&nbsp;&nbsp;Hydroxypropyl cellulose</p><p>-&nbsp;&nbsp;Croscarmellose sodium</p><p>-&nbsp;&nbsp;Magnesium stearate</p><p>-&nbsp;&nbsp;Lactose monohydrate</p><p>Film coating:</p><p>-&nbsp;&nbsp;Hypromellose</p><p>-&nbsp;&nbsp;Polyethylene glycol</p><p>-&nbsp;&nbsp;Titanium dioxide</p><p>-&nbsp;&nbsp;Talc</p><p>-&nbsp;&nbsp;Ferric oxide red</p><p>Printing ink:</p><p>-&nbsp;&nbsp;Gray F1.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum blisters.</p><p>Pack size: 28 film-coated tablets.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 4980170            
Fax: + (966-11) 4980187
e-mail: medical@jpi.com.sa

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                23 October 2018.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>